CUSIP: 40434H104
Q2 2015 13F Holders as of 30 Jun 2015
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
3,695,159
-
Share change
-
+3,695,159
-
Total reported value
-
$41,202,000
-
Price per share
-
$11.15
-
Number of holders
-
22
-
Value change
-
+$41,202,000
-
Number of buys
-
22
Quarterly Holders Quick Answers
What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 40434H104:
Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q2 2015
As of 30 Jun 2015,
HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by
22 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,695,159 shares.
The largest 10 holders included
Novo A/S, FMR LLC, BlackRock Advisors LLC, PUTNAM INVESTMENTS LLC, Cormorant Asset Management, LLC, BlackRock Group LTD, EMERALD MUTUAL FUND ADVISERS TRUST, Alyeska Investment Group, L.P., VANGUARD GROUP INC, and BlackRock Investment Management, LLC.
This page lists
22
institutional shareholders reporting positions in this security
for the Q2 2015 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.